2026 Q1 Portfolio Activity
In 2026 Q1, Octagon Capital Advisors LP maintained a portfolio of 35 distinct positions. The most significant new addition was DEFINIUM THERAPEUTICS INC, now representing 5.10% of the total fund value. They heavily accumulated shares in ALUMIS INC, increasing the position by 11.9%. The fund also reduced its exposure to GOSSAMER BIO INC by 44.3%.
Position History
hover any row below to update
Loading…
Total Positions
35
Quarter
2026 Q1
Top Holding
DNTH (18.1%)
Top 10 Concentration
68.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-35 of 35
Octagon Capital Advisors LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 18.08% | 12.09% |
#1
1
Prev: #2
|
6.5 |
—
|
-470,000 | -19.4% |
P
S
|
1,946,667 | $163,364,295 |
$23.40
+347.8%
|
2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 10.01% | 10.13% |
#2
1
Prev: #3
|
6.5 |
—
|
no change | no change |
P
S
|
2,350,000 | $90,451,500 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 8.34% | 12.38% |
#3
2
Prev: #1
|
4.8 |
—
|
-79,000 | -10.4% |
P
S
|
677,000 | $75,383,950 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 6.90% | 3.00% |
#4
8
Prev: #12
|
5.3 |
—
|
300,000 | 11.9% |
P
S
|
2,830,700 | $62,360,321 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 5.10% | — |
#5
Prev: #—
|
6.0 |
—
|
2,440,000 | — |
NEW
|
2,440,000 | $46,116,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 5.03% | 4.81% |
#6
1
Prev: #7
|
3.0 |
—
|
no change | no change |
P
S
|
1,971,054 | $45,472,216 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 4.38% | 5.92% |
#7
3
Prev: #4
|
2.8 |
—
|
no change | no change |
P
S
|
8,859,911 | $39,603,802 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 3.92% | 5.05% |
#8
2
Prev: #6
|
1.6 |
—
|
-110,000 | -20.6% |
P
S
|
425,000 | $35,398,250 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 3.46% | — |
#9
Prev: #—
|
4.9 |
—
|
338,900 | — |
NEW
|
338,900 | $31,307,582 | 2022 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 3.38% | 2.57% |
#10
5
Prev: #15
|
3.4 |
—
|
150,000 | 9.4% |
P
S
|
1,748,000 | $30,572,520 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 3.30% | 2.28% |
#11
7
Prev: #18
|
2.3 |
—
|
no change | no change |
P
S
|
750,000 | $29,790,000 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 3.23% | 2.50% |
#12
4
Prev: #16
|
3.3 |
—
|
176,667 | 13.9% |
P
S
|
1,450,000 | $29,188,500 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 3.15% | — |
#13
Prev: #—
|
4.8 |
—
|
490,000 | — |
NEW
|
490,000 | $28,493,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 3.09% | — |
#14
Prev: #—
|
4.7 |
—
|
530,000 | — |
NEW
|
530,000 | $27,941,600 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.97% | 3.87% |
#15
6
Prev: #9
|
3.7 |
—
|
543,000 | 20.7% |
P
S
|
3,166,600 | $26,821,102 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.99% | 2.73% |
#16
3
Prev: #13
|
2.8 |
—
|
708,419 | 7.4% |
P
S
|
10,276,317 | $17,983,555 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.96% | 4.28% |
#17
9
Prev: #8
|
0.8 |
—
|
-1,330,000 | -47.2% |
P
S
|
1,485,000 | $17,716,050 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 1.91% | — |
#18
Prev: #—
|
4.3 |
—
|
270,000 | — |
NEW
|
270,000 | $17,263,800 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
AKTIS ONCOLOGY ...
|
|
Unknown | 1.90% | — |
#19
Prev: #—
|
4.3 |
—
|
960,847 | — |
NEW
|
960,847 | $17,189,553 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 1.52% | — |
#20
Prev: #—
|
4.1 |
—
|
5,250,000 | — |
NEW
|
5,250,000 | $13,755,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DTIL
PRECISION BIOSC...
|
Healthcare | 1.36% | 0.97% |
#21
3
Prev: #24
|
2.5 |
—
|
318,737 | 16.6% |
P
S
|
2,236,732 | $12,302,026 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DBVT
DBV TECHNOLOGIE...
|
Healthcare | 1.33% | 1.34% |
#22
Prev: #22
|
1.5 |
—
|
no change | no change |
P
S
|
574,200 | $11,995,038 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
UNCY
UNICYCIVE THERA...
|
Healthcare | 0.73% | 0.70% |
#23
3
Prev: #26
|
1.3 |
—
|
no change | no change |
P
S
|
1,000,000 | $6,580,000 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.71% | 1.59% |
#24
3
Prev: #21
|
0.3 |
—
|
-324,110 | -31.1% |
P
S
|
719,000 | $6,435,050 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.70% | 2.08% |
#25
5
Prev: #20
|
0.3 |
—
|
-625,000 | -36.2% |
P
S
|
1,100,000 | $6,314,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.52% | 2.26% |
#26
7
Prev: #19
|
0.2 |
—
|
-506,465 | -75.4% |
P
S
|
165,000 | $4,661,250 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 0.37% | — |
#27
Prev: #—
|
3.6 |
—
|
791,555 | — |
NEW
|
791,555 | $3,300,784 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
EVMN
EVOMMUNE INC
|
Healthcare | 0.37% | 1.04% |
#28
5
Prev: #23
|
0.1 |
—
|
-356,528 | -71.3% |
P
S
|
143,472 | $3,298,421 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 0.28% | 5.24% |
#29
24
Prev: #5
|
0.1 |
—
|
-6,165,371 | -44.3% |
P
S
|
7,750,000 | $2,545,875 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.00% | 0.55% |
Sold All 😨
(Was: #27) |
0.0 |
—
|
-700,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRBP
CORBUS PHARMACE...
|
Healthcare | 0.00% | 0.94% |
Sold All 😨
(Was: #25) |
0.0 |
—
|
-955,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 0.00% | 2.36% |
Sold All 😨
(Was: #17) |
0.0 |
—
|
-574,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CDTX
CIDARA THERAPEU...
|
Unknown | 0.00% | 2.68% |
Sold All 😨
(Was: #14) |
0.0 |
—
|
-100,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CGON
CALL
CG ONCOLOGY INC
|
CALL Option | 0.00% | 3.02% |
Sold All 😨
(Was: #11) |
0.0 |
—
|
-600,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MNMD
MIND MEDICINE M...
|
Unknown | 0.00% | 3.63% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-2,230,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-35 of 35 holdings